title: Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
abstract: Renal cell carcinoma (RCC) is the most common type of kidney cancers in adults, and metastasis represents the major cause of mortality of RCC patients. The Y-box binding protein 1 (YB1) is a multifunctional oncoprotein in various malignancies. Enhancer of zeste homolog 2 (EZH2), a polycomb histone methyltransferase, is a key epigenetic modifier implicated in various cancer metastasis. However, the expression patterns and clinical correlations of both YB1 and EZH2 in RCC remain largely unclear. In this study, the expression of YB1 and EZH2 were examined using immunohistochemistry staining in a study cohort including 165 RCC and 80 tumor adjacent normal tissues. RCC tissues showed a significant higher nuclear expression of YB1 (p < 0.001) and EZH2 (p < 0.001) as compared with the normal counterparts. In addition, YB1 and EZH2 nuclear overexpression were found to be positively associated with RCC stage (p < 0.001 and p = 0.005), Fuhrman tumor grade (p = 0.022 and p = 0.044), and metastasis (p < 0.001 and p = 0.009). Overall survival analysis indicated patients with YB1 (p = 0.004, HR 5.656 (2.006-10.944)) and/or EZH2 (p = 0.006, HR 4.551 (2.124-9.438)) nuclear overexpression correlated with poor survival. More interestingly, YB1 and EZH2 nuclear expression was correlated (p = 0.005). Further studies demonstrated that EZH2 expression was significantly downregulated in YB1 knockdown RCC cell lines. Functionally, YB1 knockdown inhibited RCC invasion in vitro. In conclusion, YB1 and EZH2 expression was correlated and associated with RCC incidence, tumor stage, grade, metastasis, and survival.
authors: Department of Urology, Tianjin Institute of Urology, Tianjin Medical University Second Hospital, Tianjin, 300211, China.
authors: Yong
authors: Y
authors: Wang
authors: School of Laboratory Medicine, Tianjin Medical University, Tianjin, 300203, China.
authors: Yajing
authors: Y
authors: Chen
authors: Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.
authors: Hua
authors: H
authors: Geng
authors: Department of Urology, Children's Hospital of Hebei Province, Shijiazhuang, 050031, China.
authors: Can
authors: C
authors: Qi
authors: School of Laboratory Medicine, Tianjin Medical University, Tianjin, 300203, China.
authors: Yunde
authors: Y
authors: Liu
authors: School of Laboratory Medicine, Tianjin Medical University, Tianjin, 300203, China. danyue0705@sina.cn.
authors: Dan
authors: D
authors: Yue
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000473:pathology; D049109:Cell Proliferation / Q000235:genetics; D018572:Disease-Free Survival; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D063151:Polycomb Repressive Complex 2 / Q000096:biosynthesis* / Q000235:genetics; D011379:Prognosis; D051840:Y-Box-Binding Protein 1 / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D051840:Y-Box-Binding Protein 1; C070856:YBX1 protein, human; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2
keywords: Enhancer of zeste homolog 2; Nuclear expression; Renal cell carcinoma; Y-Box-binding protein 1